Efficacy of bamlanivimab for COVID-19 may vary with antibody status
Improving medication treatment leads to dramatic gains in emergency department care for opioid use disorder
23 December 2021Omicron hospitalisation rate up to 70% lower: UK govt agency
23 December 2021Efficacy of bamlanivimab for COVID-19 may vary with antibody status
(HealthDay)—Among patients hospitalized with COVID-19, the efficacy and safety of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing monoclonal antibody bamlanivimab varies according to whether endogenous neutralizing antibodies (nAbs) are present, according to a study published online Dec. 21 in the Annals of Internal Medicine.
